METHOD

1 . A method for treating a solid cancer which comprises the step of administering a cell to a subject, wherein the cell comprises a nucleic acid sequence encoding interleukin 12 (IL-12) downstream of a frame-slip motif (FSM) or a translational readthrough motif (TRM).

2 . (canceled)

3 . A method according to claim 1 , wherein the nucleic acid sequence encoding IL-12, encodes “flexi-IL-12”: a fusion between IL-12α and IL-12β subunits, joined by a linker.

4 - 10 . (canceled)

11 . A method according to claim 1 , wherein the cell is a tumour infiltrating immune cell.

12 . (canceled)

13 . A method according to claim 1 , wherein the cell expresses a chimeric antigen receptor (CAR) or engineered T-cell receptor (TCR)

14 . A method according to claim 13 , wherein the CAR or engineered TCR binds to one of the following target antigens: disialoganglioside (GD2); epidermal growth factor receptor (EGFR), Epithelial cell adhesion molecule (EpCAM), Glypican 3 (GPC3), human epidermal growth factor receptor (HER2), L1CAM, Mucin 1 (MUC1), Prostate-specific membrane antigen (PSMA).

15 - 16 . (canceled)

17 . A method according to claim 1 , wherein the cell also expresses a dominant negative SHP2; and/or a dominant negative TGFβ receptor.

18 . A method according to claim 1 , wherein the cell also expresses a chimeric cytokine receptor.

19 . A method according to claim 1 , wherein the cell also expresses one or more additional cytokine(s) or chemokine(s).

20 . A method according to claim 19 , wherein the cell expresses one or more of the following: IL-7, IL-15, CCL19, CXCL12.

21 - 24 . (canceled)

25 . A method according to claim 1 for the treatment of small cell lung cancer (SCLC), melanoma, renal cell cancer (RCC), hepatocellular carcinoma (HCC), ovarian cancer, pancreatic cancer, neuroblastoma, osteosarcoma.

26 . A method according to claim 1 wherein the cell expresses a CAR or engineered TCR which binds a target antigen and expression of the target antigen on the solid tumour is heterogeneous.

27 . A method according to claim 1 , wherein the cell induces epitope spreading in an anti-tumour immune response in the subject.

28 . A method according to claim 1 for inducing infiltration of immune cells into a tumour mass in the subject, such that they induce an anti-tumour immune response.

29 - 30 . (canceled)

31 . A cell which expresses a chimeric antigen receptor (CAR) and comprises;

a nucleic acid sequence encoding interleukin 12 (IL-12) downstream of a frame-slip motif (FSM) or a translational readthrough motif (TRM); and

one or more heterologous nucleic acid sequence(s) encoding one or more additional cytokine(s) or chemokine(s).

32 . A cell according to claim 31 , wherein the one or more heterologous nucleic acid sequence(s) encode one or more of the following: IL-7, IL-15, CCL19, CXCL12.

33 - 36 . (canceled)

37 . A nucleic acid construct comprising:

(i) a nucleic acid sequence encoding a chimeric antigen receptor (CAR);

(ii) a nucleic acid sequence encoding interleukin 12 (IL-12) downstream of a frame-slip motif (FSM) or a translational readthrough motif (TRM); and

(iii) one or more nucleic acid sequence(s) encoding one or more additional cytokine(s) or chemokine(s).

38 . A vector comprising a nucleic acid construct according to claim 37 .

39 . A kit of vectors, comprising:

(i) a vector comprising a nucleic acid sequence encoding a chimeric antigen receptor (CAR);

(ii) a vector comprising a nucleic acid sequence encoding interleukin 12 (IL-12) downstream of a frame-slip motif (FSM) or a translational readthrouqh motif (TRM); and

(iii) vector comprising one or more nucleic acid sequence(s) encoding one or more additional cytokine(s) or chemokine(s).

40 . A method for making a cell according to claim 31 , which comprises the step of transfecting or transducing a cell with:

i) a nucleic acid sequence encoding a chimeric antigen receptor (CAR);

(ii) a nucleic acid sequence encoding interleukin 12 (IL-12) downstream of a frame-slip motif (FSM) or a translational readthrough motif (TRM); and

(iii) one or more nucleic acid sequence(s) encoding one or more additional cytokine(s) or chemokine(s).